Ocular Therapeutix, Inc. is a high-risk healthcare company based in the United States. Specializing in eye disease therapies, they use innovative hydrogel technology to deliver treatments to the eye. With a focus on ESG, their product pipeline includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT aimed at enhancing current eye-drop treatments.